2023 World Conference on Lung Cancer (Posters)-EP05.01. Prognosis in Terms of Invasive Non-mucinous Adenocarcinoma Grading System

EP05.01. Prognosis in Terms of Invasive Non-mucinous Adenocarcinoma Grading System - PDF(Slides)

Pdf Summary

This study aimed to analyze the prognosis of invasive non-mucinous adenocarcinoma (AD) based on a new grading system proposed in the 5th edition of the WHO classification. The study included 257 patients with lung AD who underwent surgical resection. The grading system categorized tumors into three grades based on the pattern of differentiation. The study analyzed various clinicopathological factors and their association with tumor grade and prognosis.<br /><br />The results showed that as the tumor grade progressed, several factors, including smoking rate, PET SUV value, CEA value, tumor size, invasive size, T factor, N factor, pl factor, pm factor, ly factor, v factor, and STAS, increased. There were significant differences in imaging findings, such as tumor size and PET/CT, between Grade 2 and Grade 3 tumors. Additionally, there were differences in the status of EGFR mutation and PD-L1 expression.<br /><br />In terms of prognosis, there was no significant difference in overall survival among the different grades. However, there was a clear stratification in recurrence-free survival, with higher grades showing lower survival rates. However, in multivariate analysis, the grading system did not emerge as an independent prognostic factor.<br /><br />In conclusion, this study found that as the grade of invasive non-mucinous AD increased, the recurrence rate also increased. The grading system seemed to reflect tumor malignancy, but it was not an independent prognostic factor. Further research is needed to validate these findings and evaluate the clinical utility of the grading system.

Asset Subtitle

Toshimasa Okazaki

Meta Tag

Speaker Toshimasa Okazaki

Topic Pulmonology & Staging

Keywords

invasive non-mucinous adenocarcinoma

prognosis

grading system

WHO classification

lung AD

tumor grade

recurrence-free survival

EGFR mutation

PD-L1 expression

clinical utility